What is the projected market valuation of Tenofovir Disoproxil Fumarate by 2035?

The projected market valuation for Tenofovir Disoproxil Fumarate is expected to reach 4.368 USD Billion by 2035. Read More

What was the market valuation of Tenofovir Disoproxil Fumarate in 2024?

The overall market valuation of Tenofovir Disoproxil Fumarate was 2.205 USD Billion in 2024. Read More

What is the expected CAGR for the Tenofovir Disoproxil Fumarate Market during the forecast period?

The expected CAGR for the Tenofovir Disoproxil Fumarate Market from 2025 to 2035 is 6.41%. Read More

What are the main routes of administration for Tenofovir Disoproxil Fumarate?

The main routes of administration for Tenofovir Disoproxil Fumarate are oral and intravenous, with oral formulations valued at 2.8 USD Billion and intravenous at 1.568 USD Billion by 2035. Read More

What indications are associated with Tenofovir Disoproxil Fumarate?

Indications for Tenofovir Disoproxil Fumarate include HIV Pre-Exposure Prophylaxis, HIV Treatment, and Hepatitis B Virus Infection, with HIV Treatment projected to reach 2.2 USD Billion by 2035. Read More

What is the expected market size for Tenofovir Disoproxil Fumarate in HIV-Positive Adults by 2035?

The market size for Tenofovir Disoproxil Fumarate in HIV-Positive Adults is expected to reach 2.2 USD Billion by 2035. Read More

How does the dosage form impact the market for Tenofovir Disoproxil Fumarate?

The dosage form impacts the market significantly, with once-daily regimens projected to reach 2.2 USD Billion by 2035, compared to twice-daily regimens at 2.168 USD Billion. Read More

What formulations are available for Tenofovir Disoproxil Fumarate?

Available formulations for Tenofovir Disoproxil Fumarate include tablets, projected to reach 2.8 USD Billion, and oral solutions, expected to reach 1.568 USD Billion by 2035. Read More

What is the market outlook for Tenofovir Disoproxil Fumarate in HIV-Exposed Newborns and Infants?

The market outlook for Tenofovir Disoproxil Fumarate in HIV-Exposed Newborns and Infants is projected to grow to 0.968 USD Billion by 2035. Read More

Tenofovir Disoproxil Fumarate Market

Q: Which companies are the key players in the Tenofovir Disoproxil Fumarate Market?

Key players in the market include Gilead Sciences, Mylan, Teva Pharmaceuticals, Cipla, Aurobindo Pharma, Hetero Labs, Zydus Cadila, Sandoz, and Sun Pharmaceutical Industries. Read More

ID: MRFR/HC/28502-HCR

128 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Tenofovir Disoproxil Fumarate Market Research Report By Route of Administration (Oral, Intravenous), By Indication (HIV Pre-Exposure Prophylaxis (PrEP), HIV Treatment, Hepatitis B Virus Infection), By Patient Population (HIV-Positive Adults, HIV-Positive Adolescents, HIV-Exposed Newborns and Infants), By Dose (Once-Daily, Twice-Daily), By Formulation (Tablets, Oral Solution) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Tenofovir Disoproxil Fumarate Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.41%

2024 Market Size$ 2.2 Billion

2025 Market Size$ 2.35 Billion

2035 Market Size$ 4.37 Billion

Key Players

Gilead Sciences

Mylan

Teva Pharmaceuticals

Cipla

Aurobindo Pharma

Hetero Labs

Trends

Rising Awareness and Education
Regulatory Changes and Approvals
Shift Towards Generic Versions

Opportunities

Increasing Prevalence of HIV
Government Initiatives and Funding
Emerging Markets and Economic Growth

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Route of Administration (USD Billion)
  1. 4.1.1 Oral
  2. 4.1.2 Intravenous
2. 4.2 Healthcare, BY Indication (USD Billion)
  1. 4.2.1 HIV Pre-Exposure Prophylaxis (PrEP)
  2. 4.2.2 HIV Treatment
  3. 4.2.3 Hepatitis B Virus Infection
3. 4.3 Healthcare, BY Patient Population (USD Billion)
  1. 4.3.1 HIV-Positive Adults
  2. 4.3.2 HIV-Positive Adolescents
  3. 4.3.3 HIV-Exposed Newborns and Infants
4. 4.4 Healthcare, BY Dose (USD Billion)
  1. 4.4.1 Once-Daily
  2. 4.4.2 Twice-Daily
5. 4.5 Healthcare, BY Formulation (USD Billion)
  1. 4.5.1 Tablets
  2. 4.5.2 Oral Solution
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Gilead Sciences (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Mylan (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Teva Pharmaceuticals (IL)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Cipla (IN)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Aurobindo Pharma (IN)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Hetero Labs (IN)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Zydus Cadila (IN)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sandoz (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sun Pharmaceutical Industries (IN)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 US MARKET ANALYSIS BY INDICATION
5. 6.5 US MARKET ANALYSIS BY PATIENT POPULATION
6. 6.6 US MARKET ANALYSIS BY DOSE
7. 6.7 US MARKET ANALYSIS BY FORMULATION
8. 6.8 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
9. 6.9 CANADA MARKET ANALYSIS BY INDICATION
10. 6.10 CANADA MARKET ANALYSIS BY PATIENT POPULATION
11. 6.11 CANADA MARKET ANALYSIS BY DOSE
12. 6.12 CANADA MARKET ANALYSIS BY FORMULATION
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
15. 6.15 GERMANY MARKET ANALYSIS BY INDICATION
16. 6.16 GERMANY MARKET ANALYSIS BY PATIENT POPULATION
17. 6.17 GERMANY MARKET ANALYSIS BY DOSE
18. 6.18 GERMANY MARKET ANALYSIS BY FORMULATION
19. 6.19 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
20. 6.20 UK MARKET ANALYSIS BY INDICATION
21. 6.21 UK MARKET ANALYSIS BY PATIENT POPULATION
22. 6.22 UK MARKET ANALYSIS BY DOSE
23. 6.23 UK MARKET ANALYSIS BY FORMULATION
24. 6.24 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
25. 6.25 FRANCE MARKET ANALYSIS BY INDICATION
26. 6.26 FRANCE MARKET ANALYSIS BY PATIENT POPULATION
27. 6.27 FRANCE MARKET ANALYSIS BY DOSE
28. 6.28 FRANCE MARKET ANALYSIS BY FORMULATION
29. 6.29 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
30. 6.30 RUSSIA MARKET ANALYSIS BY INDICATION
31. 6.31 RUSSIA MARKET ANALYSIS BY PATIENT POPULATION
32. 6.32 RUSSIA MARKET ANALYSIS BY DOSE
33. 6.33 RUSSIA MARKET ANALYSIS BY FORMULATION
34. 6.34 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
35. 6.35 ITALY MARKET ANALYSIS BY INDICATION
36. 6.36 ITALY MARKET ANALYSIS BY PATIENT POPULATION
37. 6.37 ITALY MARKET ANALYSIS BY DOSE
38. 6.38 ITALY MARKET ANALYSIS BY FORMULATION
39. 6.39 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
40. 6.40 SPAIN MARKET ANALYSIS BY INDICATION
41. 6.41 SPAIN MARKET ANALYSIS BY PATIENT POPULATION
42. 6.42 SPAIN MARKET ANALYSIS BY DOSE
43. 6.43 SPAIN MARKET ANALYSIS BY FORMULATION
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY INDICATION
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY PATIENT POPULATION
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY DOSE
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY FORMULATION
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
51. 6.51 CHINA MARKET ANALYSIS BY INDICATION
52. 6.52 CHINA MARKET ANALYSIS BY PATIENT POPULATION
53. 6.53 CHINA MARKET ANALYSIS BY DOSE
54. 6.54 CHINA MARKET ANALYSIS BY FORMULATION
55. 6.55 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
56. 6.56 INDIA MARKET ANALYSIS BY INDICATION
57. 6.57 INDIA MARKET ANALYSIS BY PATIENT POPULATION
58. 6.58 INDIA MARKET ANALYSIS BY DOSE
59. 6.59 INDIA MARKET ANALYSIS BY FORMULATION
60. 6.60 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
61. 6.61 JAPAN MARKET ANALYSIS BY INDICATION
62. 6.62 JAPAN MARKET ANALYSIS BY PATIENT POPULATION
63. 6.63 JAPAN MARKET ANALYSIS BY DOSE
64. 6.64 JAPAN MARKET ANALYSIS BY FORMULATION
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY INDICATION
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY PATIENT POPULATION
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY DOSE
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY FORMULATION
70. 6.70 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
71. 6.71 MALAYSIA MARKET ANALYSIS BY INDICATION
72. 6.72 MALAYSIA MARKET ANALYSIS BY PATIENT POPULATION
73. 6.73 MALAYSIA MARKET ANALYSIS BY DOSE
74. 6.74 MALAYSIA MARKET ANALYSIS BY FORMULATION
75. 6.75 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
76. 6.76 THAILAND MARKET ANALYSIS BY INDICATION
77. 6.77 THAILAND MARKET ANALYSIS BY PATIENT POPULATION
78. 6.78 THAILAND MARKET ANALYSIS BY DOSE
79. 6.79 THAILAND MARKET ANALYSIS BY FORMULATION
80. 6.80 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
81. 6.81 INDONESIA MARKET ANALYSIS BY INDICATION
82. 6.82 INDONESIA MARKET ANALYSIS BY PATIENT POPULATION
83. 6.83 INDONESIA MARKET ANALYSIS BY DOSE
84. 6.84 INDONESIA MARKET ANALYSIS BY FORMULATION
85. 6.85 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
86. 6.86 REST OF APAC MARKET ANALYSIS BY INDICATION
87. 6.87 REST OF APAC MARKET ANALYSIS BY PATIENT POPULATION
88. 6.88 REST OF APAC MARKET ANALYSIS BY DOSE
89. 6.89 REST OF APAC MARKET ANALYSIS BY FORMULATION
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
92. 6.92 BRAZIL MARKET ANALYSIS BY INDICATION
93. 6.93 BRAZIL MARKET ANALYSIS BY PATIENT POPULATION
94. 6.94 BRAZIL MARKET ANALYSIS BY DOSE
95. 6.95 BRAZIL MARKET ANALYSIS BY FORMULATION
96. 6.96 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
97. 6.97 MEXICO MARKET ANALYSIS BY INDICATION
98. 6.98 MEXICO MARKET ANALYSIS BY PATIENT POPULATION
99. 6.99 MEXICO MARKET ANALYSIS BY DOSE
100. 6.100 MEXICO MARKET ANALYSIS BY FORMULATION
101. 6.101 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
102. 6.102 ARGENTINA MARKET ANALYSIS BY INDICATION
103. 6.103 ARGENTINA MARKET ANALYSIS BY PATIENT POPULATION
104. 6.104 ARGENTINA MARKET ANALYSIS BY DOSE
105. 6.105 ARGENTINA MARKET ANALYSIS BY FORMULATION
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT POPULATION
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DOSE
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY PATIENT POPULATION
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY DOSE
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY PATIENT POPULATION
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY DOSE
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION
122. 6.122 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
123. 6.123 REST OF MEA MARKET ANALYSIS BY INDICATION
124. 6.124 REST OF MEA MARKET ANALYSIS BY PATIENT POPULATION
125. 6.125 REST OF MEA MARKET ANALYSIS BY DOSE
126. 6.126 REST OF MEA MARKET ANALYSIS BY FORMULATION
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY PATIENT POPULATION, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY PATIENT POPULATION, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY DOSE, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY DOSE, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY FORMULATION, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY FORMULATION, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.2.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.2.5 BY FORMULATION, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.3.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.3.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.3.5 BY FORMULATION, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.4.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.4.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.4.5 BY FORMULATION, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.5.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.5.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.5.5 BY FORMULATION, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.6.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.6.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.6.5 BY FORMULATION, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.7.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.7.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.7.5 BY FORMULATION, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.8.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.8.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.8.5 BY FORMULATION, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.9.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.9.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.9.5 BY FORMULATION, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.10.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.10.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.10.5 BY FORMULATION, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.11.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.11.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.11.5 BY FORMULATION, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.12.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.12.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.12.5 BY FORMULATION, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.13.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.13.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.13.5 BY FORMULATION, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.14.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.14.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.14.5 BY FORMULATION, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.15.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.15.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.15.5 BY FORMULATION, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.16.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.16.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.16.5 BY FORMULATION, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.17.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.17.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.17.5 BY FORMULATION, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.18.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.18.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.18.5 BY FORMULATION, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.19.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.19.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.19.5 BY FORMULATION, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.20.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.20.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.20.5 BY FORMULATION, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.21.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.21.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.21.5 BY FORMULATION, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.22.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.22.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.22.5 BY FORMULATION, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.23.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.23.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.23.5 BY FORMULATION, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.24.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.24.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.24.5 BY FORMULATION, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.25.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.25.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.25.5 BY FORMULATION, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.26.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.26.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.26.5 BY FORMULATION, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.27.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.27.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.27.5 BY FORMULATION, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.28.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.28.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.28.5 BY FORMULATION, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.29.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.29.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.29.5 BY FORMULATION, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  2. 7.30.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.30.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY DOSE, 2025-2035 (USD Billion)
  5. 7.30.5 BY FORMULATION, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Tenofovir Disoproxil Fumarate Market Segmentation

Tenofovir Disoproxil Fumarate Market By Route of Administration (USD Billion, 2025-2035)

Oral
Intravenous

Tenofovir Disoproxil Fumarate Market By Indication (USD Billion, 2025-2035)

HIV Pre-Exposure Prophylaxis (PrEP)
HIV Treatment
Hepatitis B Virus Infection

Tenofovir Disoproxil Fumarate Market By Patient Population (USD Billion, 2025-2035)

HIV-Positive Adults
HIV-Positive Adolescents
HIV-Exposed Newborns and Infants

Tenofovir Disoproxil Fumarate Market By Dose (USD Billion, 2025-2035)

Once-Daily
Twice-Daily

Tenofovir Disoproxil Fumarate Market By Formulation (USD Billion, 2025-2035)

Tablets
Oral Solution

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”